Highlights MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 30 April 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 March 2024 (Q3 ...
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 29 April 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that important new data on its lead drug candidate ATH434 was presented at the World Orphan Drug Congress USA 2024 in ...
– ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2 Baseline Data Confirm Approach to Target Biomarkers for Slowing Disease Progression – – 12-Month Data from bioMUSE Study Shows Key Biomarker is Associated with Disease Progression in MSA – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA ...
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 10 April 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that new data on ATH434 will be presented at the World Orphan Drug Congress USA 2024 taking place April 23-25, 2024 ...
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 26 March 2024. Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received a A$3.9 million cash refund from the Australian Taxation Office under the Australian Government’s Research and ...
– Company Now Fully Funded Through Data Readout for Primary Phase 2 Clinical Trial – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 23 February 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received binding commitments for ...
– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2 Clinical Trial – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 20 February 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), ...
– ATH434-201 Trial on Track to Complete in November 2024 – – Top-Line Data Expected in January 2025 – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 6 February 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an ...
Not for release to US wire services or distribution in the United States MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 2 February 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that its Securities Purchase Plan (SPP) has been ...
Receive news from Alterity Therapeutics
